BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $12.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by Evercore ISI from $10.00 to $12.00 in a research note released on Monday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

A number of other equities analysts have also weighed in on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Needham & Company LLC lifted their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday. Finally, Barclays boosted their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $15.17.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $7.23 on Monday. The business has a fifty day simple moving average of $7.59 and a 200-day simple moving average of $7.61. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.88. The company has a market cap of $1.50 billion, a P/E ratio of -11.85 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. During the same period in the prior year, the company earned ($0.19) EPS. The company’s revenue was up 35.1% compared to the same quarter last year. Sell-side analysts expect that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in BCRX. Deerfield Management Company L.P. Series C raised its position in BioCryst Pharmaceuticals by 62.9% in the second quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock valued at $50,279,000 after purchasing an additional 3,140,804 shares during the period. Geode Capital Management LLC grew its stake in shares of BioCryst Pharmaceuticals by 2.7% in the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after buying an additional 127,708 shares in the last quarter. Fisher Asset Management LLC raised its holdings in shares of BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after buying an additional 481,359 shares during the period. Two Sigma Advisers LP lifted its position in BioCryst Pharmaceuticals by 13.6% during the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock worth $16,576,000 after acquiring an additional 261,500 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its position in BioCryst Pharmaceuticals by 4.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock worth $16,444,000 after acquiring an additional 84,102 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.